Meeting
2024 ASCO Genitourinary Cancers Symposium
Survival outcomes for rural patients with advanced prostate cancer: A SEER investigation.
Authors
Liang G Qu
Monash Health, Berwick, VIC, Australia
Liang G Qu , J. Bailey Vaselkiv , Marlon Perera , Lorelei A Mucci
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Cancer Disparities
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr 22)
DOI
10.1200/JCO.2024.42.4_suppl.22
Abstract #
22
Poster Bd #
A1
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Survival outcomes associated with fewer combination ipilimumab/nivolumab doses in advanced-stage melanoma.
First Author: Vincent T Ma
Poster
2024 ASCO Breakthrough
Early circulating tumor DNA (ctDNA) changes during treatment with immune checkpoint inhibitors (ICI) as a predictor of clinical outcomes in patients (pts) with advanced stage melanoma/skin cancer.
First Author: Vincent T. Ma
Poster
2024 ASCO Genitourinary Cancers Symposium
Real-world (RW) survival and outcomes with androgen receptor pathway inhibitor (ARPI) –doublet therapy in patients (pts) with de novo metastatic castration-sensitive prostate cancer (mCSPC).
First Author: Joshua Parrish
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Benefit of immune checkpoint inhibitors (ICI) for patients with advanced esophageal squamous cell carcinoma and low PD-L1 expression: A systematic review and meta-analysis.
First Author: Mario Machado Lopes